Type 1 diabetes (T1D) is now understood as a progressive autoimmune disease that develops in stages, even before symptoms appear. This staging framework helps identify people at risk and opens up opportunities for early intervention or monitoring. One of the earliest indicators of T1D development is the presence of T1D-specific islet autoantibodies (IAb), proteins produced by the immune system that signal an ongoing autoimmune attack on insulin-producing cells.
Here's a detailed explanation of the four stages — two pre-symptomatic and two symptomatic:
- Stage 1: Two or more IAbs are present, but blood glucose levels are still normal. No symptoms are present, and insulin production is still adequate.
5-year risk of symptoms: ~44% - Stage 2: IAbs persist and blood glucose levels become abnormal due to continued β cell loss.
5-year risk: ~75% - Stage 3: Clinical symptoms appear. Diagnosis is confirmed.
Early Stage 3 may include a temporary “honeymoon phase” with reduced insulin needs. - Stage 4: Established T1D with ongoing decline in β-cell function following diagnosis.
The presence of IAbs can be detected with a simple blood test, allowing for early identification of T1D - even before symptoms appear. If a person has two or more persistent IAbs, the likelihood of developing clinical T1D approaches 100% over time. This early detection opens opportunities for closer monitoring, participation in preventive clinical trials, and potential use of therapies aimed at delaying disease progression.
Are you interested in EARLY T1D DETECTION?
Whether you're an individual, a clinician, or a research team interested in early T1D detection and you are living or working in EUROPE, you are in the right place!
Interested in learning about early signs of Type 1 Diabetes or exploring screening and monitoring options?
The INNODIA Early T1D Navigator Tool helps you quickly find clinical sites across Europe offering early-detection and monitoring programs. It only takes a few minutes and is open to everyone — whether you have a connection to T1D or are simply curious to learn more.
Early T1D Navigator Tool Page Are you a healthcare professional working in Europe and looking to integrate early T1D detection into your clinical practice?
Discover how INNODIA can support you in joining the European effort to identify T1D earlier and connect with ongoing initiatives.
INNODIA Early T1D Detection Program
Is your clinical site already running an early T1D detection or monitoring initiative?
If your center is already conducting islet autoantibody detection or monitoring individuals with early-stage T1D, you can be featured in the INNODIA Navigator. Help people easily find your program and connect with other European initiatives.
